<h4>Background</h4>Epidermal growth factor receptor (EGFR) exon 20 insertion mutations in non-small cell lung cancer (NSCLC) represent a distinct molecular subset with limited response to conventional tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.